Elections in the Bay Area’s Counties and Cities have their mark on the local landscape.
Registration: Registration Coming Soon… Annual End-Of-Year Reception Tuesday, December 6, 2016 5:30 – 8:00pm Sonoma Restaurant 223 Pennsylvania Avenue, SE, Washington, DC 20003 As the year comes to a close, CLSA is pleased to invite you to an evening of cocktails and conversation with policymakers and leaders in the California biomedical and life sciences ecosystem. … Continue reading End of Year Reception 2
content block a
In recent years, a new round of terrifying viruses has captured the public’s imagination. Ebola, H1N1, SARS, Zika and other pathogens strike rapidly, mutate without warning and pose a major threat to public health. We recently chatted with PaxVax CEO Nima Farzan about how we can better unite government and industry to prepare for these dangers.
On June 14, the Los Angeles County Board of Supervisors voted 3-0 (2 abstained) to sidestep its original drug/sharps takeback ordinance and instead support a public education and outreach campaign with quarterly takeback events, as endorsed by CLSA and a host of national industry association partners.
California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
Patients and the life sciences community have partnered to protect access to new medicines and oppose SB 1010. The bill, by Sen. Ed Hernandez, prioritizes paperwork and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at the end of the line.
San Francisco Business Times names CLSA Pres. & CEO Sara Radcliffe a “Most Influential Woman in Business”
Check out this California Life Science Association (CLSA) and Boston Consulting Group report that details trending data about the FDA’s drug review performance. The infographic report shows that the FDA has accelerated review times, descending from an average of 21 months in 2009 to 10 months in 2015, and highlights key areas for improvement moving forward.